In the COMRADE trial, did adding olaparib improve outcomes in patients receiving radium-223 for metastatic prostate cancer?
Can PSMA PET identify patients with suspicion of prostate cancer who have negative or equivocal findings on MRI?
Is there an increased risk of ipsilateral breast tumor recurrence at 10 year after ultrahypofractionated whole breast radiation?
What was the rate of local control at 5 years with SABR for RCC in the pooled analysis of the FASTRACK trials?
Answers
Yes. Median rPFS increased from 4.7 to 8.9 months in heavily pretreated patients.
Yes, in PRIMARY 2, 68Ga-PSMA PET was non-inferior at detecting clinically significant prostate cancer while letting nearly half of patients avoid biopsy.
No. 10 year outcomes from FAST-Forward showed a IBRT rate of 3.6% with 40 Gy in 15 fractions versus 2.1% with 26 Gy in 5 fractions.
98%. In the dedicated FASTRACK II long term outcomes, local control was 100% at 84 months with either 26 Gy in 1 fraction (tumors 4cm or less) or 42 Gy in 3 fractions (tumors 4-10 cm). | QuadShot News
Can PSMA PET identify patients with suspicion of prostate cancer who have negative or equivocal findings on MRI?
Is there an increased risk of ipsilateral breast tumor recurrence at 10 year after ultrahypofractionated whole breast radiation?
What was the rate of local control at 5 years with SABR for RCC in the pooled analysis of the FASTRACK trials?
Answers
Yes. Median rPFS increased from 4.7 to 8.9 months in heavily pretreated patients.
Yes, in PRIMARY 2, 68Ga-PSMA PET was non-inferior at detecting clinically significant prostate cancer while letting nearly half of patients avoid biopsy.
No. 10 year outcomes from FAST-Forward showed a IBRT rate of 3.6% with 40 Gy in 15 fractions versus 2.1% with 26 Gy in 5 fractions.
98%. In the dedicated FASTRACK II long term outcomes, local control was 100% at 84 months with either 26 Gy in 1 fraction (tumors 4cm or less) or 42 Gy in 3 fractions (tumors 4-10 cm). | QuadShot News